COVID-19 Vaccine Could Force US Dollar Crash, Warns CitiBank

The anticipated distribution of a coronavirus vaccine, coupled with additional monetary easing could spell big trouble for the US dollar come next year.

According to a Citibank research note, the US dollar could decline by as much as 20% in 2021 in the event of a successful mass vaccine distribution and further government stimulus measures. The latest Citibank forecast comes amid US-based Moderna announcing a 94.5% success rate of its COVID-19 experimental vaccine, and rival US-based Pfizer announcing a 90% efficacy rate for its vaccine.

German biotechnology company BioNTech has also created a coronavirus vaccine that appears to have a 90% success rate, while developers of Russia’s Sputnik V vaccine have also reported a 92% efficacy.

The US bank noted that the potential for the dollar crash is also dependent on the Federal Reserve’s ongoing economic support. If the central bank continues to utilize its wide array of financial tools to uphold the economy in 2021, in addition to keeping interest rates low even if inflation expectations rise, then the US yield curve could potentially steepen as well.


Information for this briefing was found via Citibank. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Gold Trade Is Shifting From Margins to Growth | Geordie Mark – Blue Jay Gold

CopAur Minerals – This PEA Has A Mine Life of What?!

Ontario’s Fast Track to Silver Production Is Starting to Matter | Frank Basa – Nord Precious Metals

Recommended

Crossroads Gold Begins 2026 Exploration at Pambula, Reports Gold In Soil Up to 24.6 g/t

Questcorp Kicks Off Fully Funded Phase 2 Drilling at La Union

Related News

FluroTech Identifies Six Sites For Its High Volume COVID-19 Antigen Test Trial

FluroTech Ltd. (TSXV: TEST) and its subsidiary FluroTest Diagnostics Systems announced today that the clinical...

Monday, May 10, 2021, 10:14:00 AM

Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19

Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered...

Monday, May 3, 2021, 09:24:15 AM

Datametrex Conducts Over 23,700 COVID-19 Tests In Q4 Across Film Industry, Generating $4.0 Million In Revenue

Datametrex AI (TSXV: DM) this morning released data related to portions of its fourth quarter...

Tuesday, January 12, 2021, 07:11:37 AM

Sona Nanotech Halts COVID-19 Rapid Saliva Test Trials, Drops Research Program

Sona Nanotech (CSE: SONA) this morning had bombshell news, in that it has discontinued its...

Friday, June 11, 2021, 08:58:10 AM

Kontrol Energy Enters Exclusive Distribution Arrangement Across First Responder And Public Transport Industries

Kontrol Energy Corp (CSE: KNR) this morning announced that it has entered into an exclusive...

Tuesday, December 1, 2020, 07:49:59 AM